1. Clinical Outcomes of Pfizer-BioNTech COVID-19 Vaccine on Children and Adolescents: Where do we Stand?
- Author
-
Ahmad Al-Qudimat, Raed Al-Zoubi, Mai Elaarag, Abdulqadir Nashwan, Afaf Hamze, Hiba Bawadi, Aksam Yassin, Aseel Assim, Omar Aboumarzouk, Ahmad Zarour, and Abdulla Al-Ansari
- Abstract
Background: The BioNTech-Pfizer vaccine is the only vaccine offered to children among all available vaccines. However, limited evidence is available about the clinical outcomes of COVID-19 vaccines, especially among children and adolescents. This review offers a comprehensive and up-to-date overview of the BioNTech-Pfizer vaccine’s current information on children and adolescents. Methods: The review was conducted following the PRISMA guidelines; a comprehensive search was performed in PubMed, Scopus, MEDLINE, and EMBASE databases for research publications COVID-19 published between December 2019 and October 2021. All studies reporting on the outcomes of vaccinating children in their respective institutes were included. Results: A total of 78 vaccinated children and adolescents from 6 studies were included. The majority of symptomatic vaccinated pediatrics were males (71%). The mean age was 15.6 years, and the BMI was 24.1. The most common clinical symptoms were found in chest pain (35%), fever (32%), and myalgia (17%). The most common cardiac symptom in the EKG results was ST elevation, and 35% of vaccinated pediatrics had elevated serum troponin. The hospitalization, including ICU admission, was lower than in unvaccinated groups. Statistically significant associations (P =
- Published
- 2022
- Full Text
- View/download PDF